Bionyra Pharma

What it does

Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory diseases. Its pipeline includes mono and multispecific antibodies with half-life extension technology, targeting novel immune pathways for deeper and more durable disease control. The lead candidate, BYN-002, is a TL1A monoclonal antibody with half-life extension (HLE) technology, currently in Phase 1 studies for inflammatory bowel disease (IBD) and other TL1A-relevant indications. BYN-003 is a first-in-class TL1A*IL-23p19 bispecific antibody with HLE, also in Phase 1. BYN-001 is an IL-25 monoclonal antibody with HLE in IND-stage for atopic dermatitis and Type 2 inflammation. The company also has additional preclinical assets.

Who it is for

Bionyra's therapies are designed for patients with severe immune-mediated inflammatory diseases, such as atopic dermatitis and inflammatory bowel disease, who do not have good treatment options. These patients often cycle through multiple therapies without achieving sustained relief or meaningful improvements in quality of life. The company aims to deliver patient-optimized treatments with greater efficacy and improved convenience.

Why it matters

Current therapies for immune-mediated inflammatory diseases often target single nodes of complex immune networks, limiting depth and durability of response. Many patients live with a high daily burden of pain, fatigue, and uncertainty. Bionyra's next-generation biologics target novel immune pathways and incorporate half-life extension technology to minimize dosing frequency, potentially offering better and longer-lasting outcomes. The company's bispecific antibody approach (BYN-003) aims to dial down multiple drivers of disease simultaneously, which could represent a significant advancement over existing treatments.

Launch signal

Bionyra Pharma launched on June 22, 2026, with an oversubscribed $165 million (€143 million) Series A financing round. The round was co-led by Jeito Capital and Sofinnova Partners, with participation from Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures. Sofinnova Partners also provided seed financing and co-founded the company alongside CEO Dr. Frédéric Marrache. The launch was announced via a press release detailing the pipeline and financing.

Brand and naming

The name "Bionyra Pharma" combines "bio" (life, biology) with "nyra" (possibly derived from "near" or evoking innovation), suggesting a focus on biological therapies. The tagline "Pioneering next-generation biologics for immune-mediated inflammatory diseases" clearly positions the company as an innovator in the immunology space. The brand emphasizes clinical-stage development and a pipeline of best-in-class candidates, projecting scientific credibility and ambition.